Considering the initial evidence on the efficacy of dabrafenib plus trametinib in BRAF K601E-mutated melanoma and lung cancers [127,128], it would be interesting to evaluate this combination in mCRPC patients harboring this specific mutation in the future. Here, BRAF is linked to lung carcinoma.